ProQR Therapeutics (PRQR) Current Leases (2019 - 2025)

ProQR Therapeutics' Current Leases history runs 7 years deep, the most recent figure standing at $1.8 million for Q4 2025.

• In Q4 2025, Current Leases rose 7.4% year-over-year to $1.8 million; the TTM figure through Dec 2025 stood at $1.8 million (up 7.4% YoY), while the FY2025 annual figure was $1.8 million, up 7.4% from the prior year.
• Current Leases came in at $1.8 million for Q4 2025 at ProQR Therapeutics, up from $1.7 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $1.8 million in Q4 2025 to a low of -$1.6 billion in Q1 2021.
• A 5-year average of -$267.4 million and a median of $1.7 million in 2023 frame the typical range for Current Leases.
• Across the five-year window, Current Leases decreased 19.36% in 2022 and gained 22.72% in 2023, its largest moves.
• ProQR Therapeutics' Current Leases stood at $1.8 million in 2021, then dropped by 19.36% to $1.4 million in 2022, then rose by 22.72% to $1.7 million in 2023, then dropped by 3.57% to $1.7 million in 2024, then advanced by 7.4% to $1.8 million in 2025.
• According to Business Quant data, Current Leases over the past three periods registered $1.8 million, $1.7 million, and $1.7 million for Q4 2025, Q4 2024, and Q4 2023 respectively.

Peer Comparison